title: Cervical cytology in serous and endometrioid endometrial cancer.
abstract: The aim of this study was to determine the frequency of abnormal cervical cytology in preoperative cervical cytology of patients diagnosed with uterine papillary serous carcinoma (UPSC) and endometrioid endometrial carcinoma (EEC). In addition, associations between abnormal cervical cytology and clinicopathologic factors were evaluated. In this multicentre study, EEC patients diagnosed at two hospitals from 1999 to 2009 and UPSC patients diagnosed at five hospitals from 1992 to 2009, were included. Revision of the histologic slides was performed systematically and independently by 3 gynecopathologists. Cervical cytology within six months before histopathologic diagnosis of endometrial carcinoma was available for 267 EEC and 80 UPSC patients. Cervical cytology with atypical, malignant, or normal endometrial cells in postmenopausal women was considered as abnormal cytology, specific for endometrial pathology. Abnormal cervical cytology was found in 87.5% of UPSC patients, compared with 37.8% in EEC patients. In UPSC, abnormal cytology was associated with extrauterine spread of disease (P=0.043). In EEC, abnormal cytology was associated with cervical involvement (P=0.034). In both EEC and UPSC patients, abnormal cervical cytology was not associated with survival. In conclusion, abnormal cervical cytology was more frequently found in UPSC patients. It was associated with extrauterine disease in UPSC patients, and with cervical involvement in EEC patients. More prospective research should be performed to assess the true clinical value of preoperative cervical cytology in endometrial cancer patients.
authors.affiliation: Department of Obstetrics and Gynecology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands. t.roelofsen@obgyn.umcn.nl
authors.forename: Thijs
authors.initials: T
authors.lastname: Roelofsen
authors.forename: Yvette P
authors.initials: YP
authors.lastname: Geels
authors.forename: Johanna M A
authors.initials: JM
authors.lastname: Pijnenborg
authors.forename: Maaike A P C
authors.initials: MA
authors.lastname: van Ham
authors.forename: Saskia F
authors.initials: SF
authors.lastname: Zomer
authors.forename: Johanna M Wiersma
authors.initials: JM
authors.lastname: van Tilburg
authors.forename: Marc P M L
authors.initials: MP
authors.lastname: Snijders
authors.forename: Albert G
authors.initials: AG
authors.lastname: Siebers
authors.forename: Johan
authors.initials: J
authors.lastname: Bulten
authors.forename: Leon F A G
authors.initials: LF
authors.lastname: Massuger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018269:Carcinoma, Endometrioid / Q000473:pathology*; D002584:Cervix Uteri / Q000473:pathology*; D015331:Cohort Studies; D018283:Cystadenocarcinoma, Papillary / Q000473:pathology*; D018284:Cystadenocarcinoma, Serous / Q000473:pathology*; D016889:Endometrial Neoplasms / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009426:Netherlands; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D014594:Uterine Neoplasms / Q000473:pathology*; D014626:Vaginal Smears